Understanding the Market | LIFETECH SCI rises over 10%, institutions expect the company's centralized procurement price adjustment related products to gradually clear in the second half of the year, focusing on industry valuation recovery

LIFETECH SCI's stock price rose by more than 10%, with an increase of 9.45% as of the time of publication, trading at HKD 2.20, with a turnover of HKD 214 million. Huazhang Securities pointed out that in 2024, the National Healthcare Security Administration will re-establish the pricing for thoracic aortic stent graft products, and the price adjustments are expected to gradually clear in the second half of 2025, improving the company's revenue and profit. CITIC Jianzhong believes that with policy relaxation and the expansion of international business, the performance and valuation of the medical device industry will undergo a recovery, and investment opportunities will continue to emerge